- Details
- Rafael Sanchez Salas, MD, from the Montsouris Institute in France joins Ashish Kamat, MD, MBBS, to provide his perspective on essential components of a radical cystectomy. Radical cystectomy is the standard of care for patients with muscle-invasive bladder cancer and those with high-grade non-muscle invasive bladder cancer, and it comes with the risk of complications and adverse outcomes. Dr. Sala...
|
- Details
- Recorded Date: June 15, 2020 Pradeep Rao joins UroToday's Bladder Cancer Center of Excellence from Mumbai, India to discuss the state of bladder cancer treatment and diagnosis in India. Dr. Rao describes issues regarding the lack of a bladder cancer registry and a variation in the quality of TURBT across India, as well as the problem arising from limited access to blue light for screening. Dr. Rao...
|
- Details
- Makarand Khochikar, MS DNB, Dip Urol, FRCS, FEBU, presents a case of a patient with muscle-invasive bladder cancer undergoing surgery to remove the bladder and urinary diversion with a neobladder. Dr. Khochikar discusses the results of the patient's cystectomy and describes how the patient showed malrotation of the gut, which required Dr. Khochikar to contemplate options during surgery as to how t...
|
- Details
- Ashish Kamat is joined by Colin Dinney to discuss the results of the SUO-CTC Phase 3 Trial of nadofaragene firadenovec for patients with non-muscle invasive bladder cancer unresponsive to BCG. Dr. Dinney presents slides and discusses how most NMIBC patients recur despite BCG therapy, and there is an unmet need for therapies in patients' refractory to BCG. Previously, Nadofaragene firadenovec was t...
|
- Details
- In this conversation moderated by Ashish Kamat, the use of trimodal therapy versus radical cystectomy for treating T2 bladder cancer is debated by Stephen Williams and Nick James. During the debate, Dr. James speaks in favor of trimodal therapy for a hypothetical patient with muscle-invasive bladder cancer, focusing on case studies and the potential for benefit of combining chemotherapeutic option...
|
- Details
- Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...
|
- Details
- Ashish Kamat, MD, MBBS is joined by Sima Porten, MD, MPH and Joshua Meeks, MD, PhD, panelist in the American Urological Association (AUA) Guidelines Case-Based Panel Discussion on Non-muscle and Muscle Invasive Bladder Cancer AUA 2020 plenary presentation. They provide their perspectives on bladder cancer patient guidelines-based management and the specific management of bladder cancer patients. B...
|
- Details
- Stephen Williams discusses the macro and microeconomics of using blue light cystoscopy with CYSVIEW ® in nonmuscle invasive bladder cancer compared to white light cystoscopy alone. Dr. Williams notes that cancer care is expected to increase from $158 to $174 billion dollars between 2010 and 2020 due to increasing cancer incidence, improved survival outcomes, and an expanding healthcare market. Cos...
|
- Details
- Ashish Kamat welcomes leading bladder cancer experts Paolo Gontero and Bernard Bochner to engage in a debate considering a hypothetical patient with nonmuscle invasive high-grade T1 disease. Dr. Bochner starts by addressing different treatment options for patients presenting with T1 disease while acknowledging that T1 disease is a spectrum and can be variably invasive. He discusses BCG as a treatm...
|
- Details
- Alicia Morgans and Sam Chang discuss the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines. Dr. Chang, a member of the bladder cancer guidelines committee, notes that while the guidelines are in the process of being updated since these were last updated in 2017, they serve as an algorithm for all clinicians on how to evaluate patients and risk stratification....
|